Compare Comcast Corporation (CMCSA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Comcast Corporation trades at $25.22 (market cap $91.02B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Comcast Corporation is far larger — about 1158.8× Inovio Pharmaceuticals Inc's market cap, and Comcast Corporation pays a 5.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CMCSA | INO | |
|---|---|---|
Market Cap | $91.02B | $78.55M |
Sector | Media | Health |
52-Week High | $32.50 | $2.87 |
52-Week Low | $21.92 | $0.66 |
Enterprise Value | $173.74B | $49.56M |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.20, down 0.63% today, with strong fundamentals including a P/E of 8.22 and net income margin of 8.97%. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI indicates potential overbought conditions. Recent earnings beats and a planned NBCUniversal spinoff provide positive catalysts, while analyst consensus remains strongly bullish with a $27.78 price target.
CMCSA presents compelling value with discounted valuation multiples and consistent cash flow generation. Key opportunities include wireless growth and media separation, while risks involve competitive pressures and potential economic headwinds affecting consumer spending. The stock offers a balanced risk-reward profile for long-term investors seeking stable returns.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
